Research Article
Comparing the Efficacy and Safety of Induction Therapies for the Treatment of Patients with Proliferative Lupus Nephritis in South Africa
Table 1
Baseline demographic and clinical characteristics of study participants.
| | | IVCYC (n = 65) | MMF (n = 19) | Total (N = 84) | value |
| | Mean age ± SD (years) | 30.3 ± 11.2 | 27.0 ± 6.9 | 29.6 ± 10.4 | 0.23 | | Female sex (%) | 74.3 | 25.7 | 88.1 | 0.07 | | Ethnicity (%) | | Black | 30.7 | 31.5 | 30.9 | 0.08 | | Mixed ancestry | 67.6 | 68.4 | 67.8 | | White | 1.5 | 0.0 | 1.1 | | Mean SBP (at biopsy) (mmHg) | 131.7 ± 20.5 | 122.9 ± 13.6 | 129.7 ± 19.4 | 0.08 | | Mean DBP at biopsy (mmHg) | 80.1 (14.2) | 73.2 ± 10.7 | 78.5 ± 13.7 | 0.05 | | mABP (at biopsy) (mmHg) | 97.4 ± 15.0 | 89.7 ± 10.9 | 95.7 ± 14.5 | 0.04 | | Use of ACE-I/ARB (%) | 89.2 | 94.7 | 90.5 | 0.47 | | Hb at biopsy (g/dl) | 9.9 ± 2.8 | 10.6 ± 2.0 | 10.1 ± 2.6 | 0.36 | | WBC at biopsy ( x 109/L) | 8.1 ± 4.5 | 6.7 ± 3.5 | 7.8 ± 4.3 | 0.23 | | Low C3 (%) | 87.5 | 78.9 | 85.5 | 0.35 | | Low C4 (%) | 69.8 | 79.0 | 72.0 | 0.44 | | Positive ANA (%) | 86.9 | 88.9 | 87.3 | 0.82 | | Positive dsDNA (%) | 90.3 | 84.2 | 88.9 | 0.46 | | Serum albumin (g/L) | 28.2 ± 6.9 | 29.5 ± 9.59 | 28.5 ± 7.5 | 0.51 | | Median SCr (IQR) (µmol/L) | 96 (65–192) | 70 (58–84) | 84.5 (62–174) | 0.02 | | Median eGFR (IQR) (ml/min/1.73 m2) | 61.91 (27.9–94.5) | 87.2 (69.6–106.8) | 69.7 (33.5–99.2) | 0.02 | | uPCR (mg/mmol) | 320 (185–585) | 290 (170–670) | 310 (170–590) | 0.92 |
|
|
IVCYC = intravenous cyclophosphamide; MMF = mycophenolate mofetil; SBP = systolic blood pressure; DBP = diastolic blood pressure; mABP = mean arterial blood pressure; ACE-I = angiotensin converting enzyme inhibitor ARB = angiotensin receptor blocker; Hb = haemoglobin; WBC = white blood cell count; ANA = antinuclear antibodies; dsDNA = double stranded DNA; SCr = serum creatinine; eGFR = estimated glomerular filtration rate; uPCR = urine protein-creatinine ratio, SD: standard deviation.
|
